Brett Favre Shares Why He Supports Odyssey Health’s New Concussion Treatment

Jul. 11, 2022
Pro Football Hall of Fame QB Brett Favre discusses why he supports an innovative new concussion treatment in development by Odyssey Health (OTC: ODYY) in this exclusive RedChip interview. Odyssey’s novel pharmaceutical compound, PRV-002, is intended for the treatment of concussion. PRV-002 is a new chemical entity administered nasally with proven in-vivo efficacy and safety in concussion models. Pre-clinical results show significantly improved sensory motor function and significantly improved memory scores. The drug is currently in a Phase 1 human trial. Visit ODYYinfo.com to learn more.

 Read More


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market